This partnership aims to improve the delivery of targeted therapies for cancer patients by expanding access to the innovative Pb-212 radioisotope
Brussels, Belgium and St. Louis, Missouri July 8, 2024 – Orchestra Life Sciences, developer of the innovative TAG1 generator designed to create Pb-212, is proud to announce a strategic partnership with Precirix, a leader in the development of precision radiopharmaceuticals using camelid single-domain antibodies as targeting vectors. This collaboration aims to enhance the availability and application of Pb-212, a promising radioisotope in the field of targeted alpha therapy (TAT) for cancer treatment. Single-domain antibodies derived from camelids, also known as VHH or nanobodies, are excellent targeting vectors for targeted radiotherapies. These single monomeric variable antibody domains combine the benefits of conventional mono-clonal antibodies and peptide approaches, with high target specificity, affinity, and stability, they are suitable for radiolabeling, rapid pharmacokinetics, efficient tumor penetration and retention while maintaining fast clearance and low immunogenicity.
Pb-212 is gaining recognition for its potential in treating various forms of cancer. Its ability to deliver high-energy alpha particles makes it an effective tool in targeted alpha therapy, which seeks to destroy cancer cells while minimizing damage to surrounding healthy tissue. By partnering with Orchestra Life Sciences and its TAG1 generator, Precirix is poised to facilitate greater access to this novel and upcoming alpha emitting isotope, advancing research and treatment options for patients worldwide.
Combining Precirix’ expertise and technology with Orchestra Life Sciences’ proficiency in isotope production will drive exciting new R&D initiatives, fostering breakthroughs in cancer therapy.
“We are thrilled to join forces with Orchestra Life Sciences to expand the availability of Pb-212 and add Pb-212 to the range of alpha-emitters for use with our CAM-TRT platform,” said Dimitrios Mantzilas, CTO of Precirix. “This partnership underscores our commitment to advancing cancer treatment and providing innovative solutions to improve patient care.”
Emilie Pelletier, CEO of Orchestra Life Sciences added, “Collaborating with Precirix marks a significant step forward in our mission to accelerate the development of targeted therapies that can make a significant difference for cancer patients. By leveraging our TAG1 generator’s capabilities to expand production we can broaden the impact of Pb-212 to accelerate the delivery of targeted therapies.”
About Orchestra Life Sciences
Orchestra Life Sciences is a technical consultancy supporting clients in cell and gene therapy and radiopharmaceuticals. As the premier radiopharmaceutical consultancy, Orchestra Life Sciences assists clients with all facets of business strategy, isotope production, supply chain, logistics, capital projects and operations. Orchestra Life Sciences is currently developing the TAG1 Generator, a proprietary and innovative generator designed to unlock the supply of Pb-212 for pre-clinical and clinical trials of targeted alpha therapies utilizing this vital radioisotope.
About Precirix
Precirix is a private biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing precision radiopharmaceuticals, using camelid single domain antibodies (sdAb) labelled with radioisotopes. The company’s Fibroblast Activation Protein (FAP)-targeting program is transitioning Precirix’ radiometal platform drugs into the clinic. Research on multiple isotopes, linker technology and combination therapies further expand the platform. CAM-H2, a HER2-directed sdAb combined with iodine-131 recently completed a Phase I clinical study. Precirix’ technology allows for a theranostic approach, where patients can be selected using an imaging version of the product, followed by a therapeutic dose for treatment.
Media Contact:
Emilie Pelletier, CEO
info@orchestralifesciences.com